Asymmetric dimethylarginine (ADMA) is a laboratory marker associated with cardiovascular risk. Elevated ADMA levels are linked with coronary heart disease and are commonly observed in conditions such as hypertension, hyperlipidemia, and type 2 diabetes mellitus. ADMA interferes with the production of nitric oxide (NO), a molecule that helps blood vessels relax and supports healthy circulation. When nitric oxide synthesis is inhibited, blood vessels tend to constrict, peripheral blood flow is reduced, and cardiac workload increases. For this reason, elevated ADMA is considered a marker of increased cardiovascular risk.
A placebo-controlled study published in Minerva Endocrinologica (2015 Dec;40(4):259–266) examined the effects of coenzyme Q10 (CoQ10) supplementation on cardiovascular risk markers in adults with type 2 diabetes. The study included 64 participants, 31 of whom received CoQ10 at a dose of 200 mg per day, while 33 received a placebo. The intervention lasted 12 weeks.
Clinical and biochemical measurements were taken before and after the trial, including ADMA, serum nitrite and nitrate levels (NOx, indicators of nitric oxide availability), hemoglobin A1c, and lipid profiles. Compared with the placebo group, participants receiving CoQ10 showed significant improvements in ADMA levels, NOx, low-density lipoprotein (LDL) cholesterol, and hemoglobin A1c.
Based on these findings, the researchers concluded that CoQ10 supplementation was associated with favorable changes in ADMA and related metabolic markers, suggesting a potential influence on cardiovascular risk factors in individuals with type 2 diabetes. As with other nutrition-based interventions, further studies are needed to clarify long-term outcomes and clinical relevance.
